The 60 minute cancel treatmentDave Lashmet’s new cancer breakthrough procedure using adaptive radiotherapy is quite interesting. Does anyone know which company he is teasing with this pitch?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Sorry, I mean the 60 Minute cancer treatment
Looks to me like Accuray (ARAY).
This post is for information sharing only for your own due diligence process and is not intended and should in no way be construed as investment advice. It represents my personal observation and opinion only and my posts are covered under the SGS disclaimer and the disclaimer on the Dr. KSS dropbox. Biotech investing is high risk.
They touted in their promotion that the company had $1B or more is sales, so probably not ARAY
Check out VRAY instead. I think it is a closer bet. Stock spikes 12% today after yesterday’s webinar. Suspect this is the stock. There is also a report on the stock from Motley Fool on 3rd Nov 2017 that explains a spike of 17% then. The stock has recorded a good ride this year since hitting a low of below $3!
Check this interview by VRAY CEO: https://stocknewsnow.com/showcommentary.php?newsartid=ANEWSID15122015100001&title=SNNLive-Video-Interview-with-ViewRay-Inc
Very sure it is VRAY now, shares raise 17% today. The company holds the patents for MRI cum radiotherapy system. Check the company website, very interesting. 4 systems sold and a backlog of about 28 machines and counting. Cost price is approximately $60M/system. System is FDA approved. Only problem is they also have Europe CE Mark, but thought this is pending according to the advertisement?
VRAY’s sales aren’t even close to $1B.
Moderator mentioned help in buying stock on foreign markets with subscription. Also stated major breakthrough results just published in last couple of days. Checked JAMA and NE and found nothing.
Found this:
http://medicalphysicsweb.org/cws/article/research/70464
Swedish company, article published 11/15, with link to original article which mentions four patients. http://iopscience.iop.org/article/10.1088/1361-6560/aa9517
However, the moderator talked about 100% with the first four patients treated; the article doesn’t talk about patient outcomes, but proof-of-concept.
Travis says it’s Elekta (ECTA-B in Stockholm, EKTAF or EKTAY OTC in the US)
https://www.stockgumshoe.com/reviews/stansberry-venture/identifying-lashmets-december-31-2017-medical-breakthrough-radical-treatment-that-could-treat-1-in-2-of-all-cancer-patients/